Lars Oddsson

Dr. Lars Oddsson

orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 June 2015 in Obesity Research & Clinical Practice
Verified
Journal Article
Closed access
PDF file
IMItshak Melzer
Itshak Melzer
LOLars Oddsson
Lars Oddsson

9 November 2020 in Frontiers in Aging Neuroscience
Verified
Journal Article
Open access
PDF file
LOLars Oddsson
Lars Oddsson
TBTeresa Bisson
Teresa Bisson
HCHelen S. Cohen
Helen S. Cohen
LJLaura Jacobs
Laura Jacobs
MKMohammad Khoshnoodi
Mohammad Khoshnoodi
SKSara R. Koehler-McNicholas
Sara R. Koehler-McNicholas
Background: Sensory peripheral neuropathy (PN) is associated with gait, balance problems and high fall risk. The walk2Wellness trial investigates effects of long-term, home-based daily use of a wearable sensory prosthesis on gait function, balance, quality of life and fall rates in PN patients. The device (Walkasins®, RxFunction Inc., MN, United States) partially substitutes lost nerve function related to plantar sensation providing directional tactile cues reflecting plantar pressure measurements during standing and walking. We tested the null hypothesis that the Functional Gait Assessment (FGA) score would remain unchanged after 10 weeks of use. Methods: Participants had PN with lost plantar sensation, gait and balance problems, an FGA score < 23 (high fall risk), and ability to sense tactile stimuli above the ankle. Clinical outcomes included FGA, Gait Speed, Timed Up&Go (TUG) and 4-Stage Balance Test. Patient-reported outcomes included Activities-Specific Balance Confidence (ABC) scale, Vestibular Disorders Activities of Daily Living Scale, PROMIS participation and satisfaction scores, pain rating, and falls. Evaluations were performed at baseline and after 2, 6, and 10 weeks. Subjects were not made aware of changes in outcomes. No additional balance interventions were allowed. Results: Forty-five participants of 52 enrolled across four sites completed in-clinic assessments. FGA scores improved from 15.0 to 19.1 (p < 0.0001), normal and fast gait speed from 0.86 m/s to 0.95 m/s (p < 0.0001) and 1.24 m/s to 1.33 m/s (p = 0.002), respectively, and TUG from 13.8 s to 12.5 s (p = 0.012). Four-Stage Balance Test did not improve. Several patient-reported outcomes were normal at baseline and remained largely unchanged. Interestingly, subjects with baseline ABC scores lower than 67% (high fall risk cut-off) increased their ABC scores (49.9% to 59.3%, p = 0.01), whereas subjects with ABC scores above 67% showed a decrease (76.6% to 71.8%, p = 0.019). Subjects who reported falls in the prior 6 months (n = 25) showed a decrease in the number of fall-risk factors (5.1 to 4.3, p = 0.023) and a decrease in fall rate (13.8 to 7.4 falls/1000 days, p = 0.014). Four pre-study non-fallers (n = 20) fell during the 10 weeks. Conclusion: A wearable sensory prosthesis presents a new way to treat gait and balance problems and manage falls in high fall-risk patients with PN. Trial registration: ClinicalTrials.gov (#NCT03538756).

30 April 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SKSara R Koehler-McNicholas
Sara R Koehler-McNicholas
LDLori Danzl
Lori Danzl
ACAlana Y Cataldo
Alana Y Cataldo
LOLars Oddsson
Lars Oddsson
Peripheral neuropathy may cause loss of sensory information from plantar cutaneous mechanoreceptors that is important for balance control and falls management. The current study investigated short-term effects of using Walkasins, an external lower-limb sensory neuroprosthesis, on clinical outcomes of balance and gait in persons who reported peripheral neuropathy and balance problems. The device replaces lost plantar sensation with tactile balance information that modulates cutaneous mechanoreceptors above the ankle where sensation is intact. Thirty-one male community-dwelling Veterans, 56–84 years old with insensate feet and balance problems participated. Initial Functional Gait Assessment, gait speed, and 4-Stage Balance Test outcomes were assessed. After initial assessment, subjects were randomly assigned to either wearing Walkasins turned ON, or OFF, and outcomes were re-assessed following a set of standardized balance exercises. Following a one-hour rest and washout period, treatments were crossed-over between groups and a third outcomes assessment was performed. Before cross-over, 10 of 15 subjects in the ON-then-OFF group improved their Functional Gait Assessment score by at least four points, the Minimal Clinically Important Difference, compared to 5 of 16 in the OFF-then-ON group. After cross-over, 7 of 16 subjects in the OFF-then-ON group improved by at least four points versus 2 of 15 in the ON-then-OFF group. ON treatment was associated with a Functional Gait Assessment improvement of 4.4 ± 3.7 points versus 1.5 ± 1.2 for the OFF treatment (p<0.01). Overall, Functional Gait Assessment scores changed from 15.2 ± 4.8 at initial assessment to 21.1 ± 5.2 after final assessment (p<0.001). At the end of the two treatment sessions, 16 of the 31 individuals had improved their Functional Gait Assessment score beyond 23, indicating normal fall-risk status. Future studies should investigate long-term benefits of the device to reduce fall risk and actual falls in patients with peripheral neuropathy and balance problems.

20 September 2022 in Frontiers in Aging Neuroscience
Verified
Journal Article
Open access
LOLars Oddsson
Lars Oddsson
TBTeresa Bisson
Teresa Bisson
HCHelen S. Cohen
Helen S. Cohen
IIIkechukwu Iloputaife
Ikechukwu Iloputaife
LJLaura Jacobs
Laura Jacobs
SKSara R. Koehler-McNicholas
Sara R. Koehler-McNicholas
Background: We recently reported that individuals with impaired plantar sensation and high fall risk due to sensory peripheral neuropathy (PN) improved gait and balance function following 10 weeks of use of Walkasins®, a wearable lower limb sensory prosthesis that provides directional specific mechanical tactile stimuli related to plantar pressure measurements during standing and walking (RxFunction Inc., Eden Prairie, MN, United States). Here, we report 26-week outcomes and compare pre- and in-study fall rates. We expected improvements in outcomes and reduced fall rates reported after 10 weeks of use to be sustained.Materials and methods: Participants had clinically diagnosed PN with impaired plantar sensation, high fall risk (Functional Gait Assessment, FGA score < 23) and ability to sense tactile stimuli above the ankle at the location of the device. Additional outcomes included 10 m Gait Speed, Timed Up and Go (TUG), Four-Stage Balance Test, and self-reported outcomes, including Activities-Specific Balance Confidence scale and Vestibular Disorders Activities of Daily Living Scale. Participants tracked falls using a calendar.Results: We assessed falls and self-reported outcomes from 44 individuals after 26 weeks of device use; 30 of them conducted in-person testing of clinical outcomes. Overall, improvements in clinical outcomes seen at 10 weeks of use remained sustained at 26 weeks with statistically significant increases compared to baseline seen in FGA scores (from 15.0 to 19.2), self-selected gait speed (from 0.89 to 0.97 m/s), and 4-Stage Balance Test (from 25.6 to 28.4 s), indicating a decrease in fall risk. Non-significant improvements were observed in TUG and fast gait speed. Overall, 39 falls were reported; 31 of them did not require medical treatment and four caused severe injury. Participants who reported falls over 6 months prior to the study had a 43% decrease in fall rate during the study as compared to self-report 6-month pre-study (11.8 vs. 6.7 falls/1000 patient days, respectively, p < 0.004), similar to the 46% decrease reported after 10 weeks of use.Conclusion: A wearable sensory prosthesis can improve outcomes of gait and balance function and substantially decreases incidence of falls during long-term use. The sustained long-term benefits in clinical outcomes reported here lessen the likelihood that improvements are placebo effects.Clinical trial registration: ClinicalTrials.gov, identifier #NCT03538756.

27 May 2015 in Frontiers in Systems Neuroscience
Verified
Journal Article
Open access
PDF file
LOLars Oddsson
Lars Oddsson
MFMarsha J. Finkelstein
Marsha J. Finkelstein
SMSarah Meissner
Sarah Meissner
Evidence-based guidelines recommend early functional rehabilitation of stroke patients when risk of patient harm can be managed. Current tools do not allow balance training under load conditions sufficiently low for acute stroke patients. This single-arm pilot study tested feasibility and safety for acute stroke survivors to use “Balance-Bed”, a technology for balance exercises in supine initially developed to emulate microgravity effects on balance. Nine acute stroke patients (50-79 yrs.) participated in 3-10 sessions over 16-46 days as part of their rehabilitation in a hospital inpatient setting. Standard inpatient measures of outcome were monitored where lack of progress from admission to discharge might indicate possible harm. Total FIM scores at admission (median 40, range 22-53) changed to (74, 50-96), Motor FIM scores from (23, 13-32) to (50, 32-68) and Berg Balance scores from (3, 0-6) to (19, 7-43) at discharge. Changes reached Minimal Clinical Important Difference for a sufficient proportion (>0.6) of the patients to indicate no harm to the patients. In addition, therapists reported the technology was safe, provided a positive experience for the patient and fit within the rehabilitation program. They reported the device should be easier to set up and exit. We conclude acute stroke patients tolerated Balance-Bed exercises such as standing on one or two legs, squats, stepping in place as well as balance perturbations provided by the therapist. We believe this is the first time it has been demonstrated that acute stroke patients can safely perform whole body balance training including balance perturbations as part of their rehabilitation program. Future studies should include a control group and compare outcomes from best practices to interventions using the Balance-Bed. In addition, the technology is relevant for countermeasure development for spaceflight and as a test-bed of balance function under microgravity-like conditions.

23 February 2026 in Frontiers in Neurology
Verified
Journal Article
Open access
PDF file
SRSutton B. Richmond
Sutton B. Richmond
LJLaura Jacobs
Laura Jacobs
CKCaleb Kumar
Caleb Kumar
YRYvonne Rumsey
Yvonne Rumsey
CTCarole A. Tucker
Carole A. Tucker
LOLars Oddsson
Lars Oddsson
Introduction: Functional mobility, or the capacity to move safely and independently, can be evaluated using performance-based physiological tests, observational assessments, or self-report tools. This study sought to develop the PROWalk™, a PROMIS-based patient-reported outcome measure of perceived gait and balance challenges, and evaluated its performance relative to the Patient-Specific Functional Scale (PSFS) in individuals with sensory peripheral neuropathy. Methods: PROWalk was developed with expert clinician input using selected items from the PROMIS item bank. It was administered via telehealth to participants with lower-extremity peripheral neuropathy ( N = 51; age 76 ± 4 years; 4 female) who were prescribed a wearable sensory prosthesis, alongside the PSFS, at baseline and again after 6 weeks. Results: Both measures displayed significant increases (i.e., improvements) over time with large effect sizes (PROWalk: rrb = −0.878; PSFS: rrb = −0.993), strong temporal correlations (PROWalk: rho = 0.684; PSFS: rho = 0.458), and upward linear trends for each instrument between baseline and 6 weeks. When normalized, the measures showed no bias, large limits of agreement, and moderate convergent validity ( rho = 0.582, p < 0.001). Discussion: Compared with broader PROMIS Physical Function short forms, PROWalk targets mobility-specific activities relevant to gait and balance. It demonstrated significant improvements in perceived functional mobility over time and strong temporal stability, supporting its use for standardized group-level comparisons. PROWalk appears to be a valid, telehealth-compatible measure for capturing self-reported functional mobility in individuals with sensory neuropathy and may address limitations of more individualized assessment tools.